However, SOX2 silencing or erlotinib treatment significantly reversed TGIF2 overexpression-promoted increase in tumor size (TGIF2-OE vs. TGIF2-OE/shSOX2; TGIF2-OE vs TGIF2-OE/Erlotinib) (Figure 7A-B). Here, SOX2 is linked to neoplasm.